Consensus Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
2.18 ^USD	-2.68%		-5.63%	-68.50%

06/05	Certain Warrants of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI
06/05	Certain Options of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI

Evolution of the average Target Price on Immix Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7efba662daec5319293c41.tWoc-4YIkDOSiNNoelSH-6juBi5ChYp0eShdGA8h9-8.xlhfuL9d2WzZ0IACMSPzzpzZcEsSw7INNVoXUWZnv7X-XjGP7SXAB_q4pA~b55e67752b655bf8b647ee3d18f5f6e7

Analyst Recommendations on Immix Biopharma, Inc.

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma	02/23/02	CI
Immix Biopharma Unit Says NXC-201 Shows 100% Overall Response Rate in Light Chain Amyloidosis Study	22/23/22	MT
Roth MKM Initiates Immix Biopharma to Buy Rating With $14 Price Target	22/23/22	MT
Immix Unit Says AL Amyloidosis Drug Candidate Showed 100% Complete Response Rate in Clinical Study	06/23/06	MT
Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study	20/22/20	MT
Immix Biopharma Says IMX-110 Candidate Elicits 50% Response Rate in Soft Tissue Sarcoma Study in Mice	12/22/12	MT
Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study	12/22/12	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.24 USD

Average target price

14 USD

Spread / Average Target

+525.00%

High Price Target

14 USD

Spread / Highest target

+525.00%

Low Price Target

14 USD

Spread / Lowest Target

+525.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immix Biopharma, Inc.

Roth MKM

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar